Upstream Bio, Inc. <UPB.O>: Truist Securities cuts target price to $25 from $43
UPB•Related News
Avalyn Pharma Q2 FY26 net loss widens to $28.94 million
AVLN•
Natera To Support New Clinical Trial Assessing ctDNA Dynamics With Latitude in Advanced Skin Cancers
NTRA•
Goldman Sachs to acquire ETF provider Neos in $2.3 billion deal - Bloomberg News
GS•
OPEC further lowers 2026 global oil demand growth forecast
XLE•
Acurx says Japan, Mexico patent offices grant new patents for DNA polymerase IIIC inhibitor antibiotics
ACXP•